Wide Ranks

KMDA

Kamada Ltd.

5.81

Top Statistics
Market Cap 334 M Forward PE 16.14 Revenue Growth 13.40 %
Current Ratio 4.07 Trailing PE 21.52 Earnings Growth 100.00 %
Profit Margins 9.75 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 9.71 Enterprise / Revenue 1.79 Price To Sales Trailing12 Months 2.16
Profitability
Profit Margins 9.75 % Operating Margins 13.28 %
Balance Sheet
Total Cash 56 M Total Cash Per Share 1.02 Total Debt 8 M
Total Debt To Equity 3.41 Current Ratio 4.07 Book Value Per Share 4.25
All Measures
Short Ratio 94.00 % Message Board Id finmb_9002466 Fax 972 8 940 6473
Shares Short Prior Month 16064 Return On Equity 0.0704 City Rehovot
Uuid a88fd904-380d-3754-b686-3fbaf4e080d7 Previous Close 5.81 First Trade Date Epoch Utc 1 B
Book Value 4.25 Beta 0.1950 Total Debt 8 M
Volume 31519 Price To Book 1.37 Fifty Two Week Low 4.60
Total Cash Per Share 1.02 Total Revenue 154 M Shares Short Previous Month Date 1 B
Target Median Price 13.00 Max Age 86400 Recommendation Mean 1.50
Sand P52 Week Change 0.3133 Operating Margins 13.28 % Last Dividend Value 0.0060
Target Mean Price 14.67 Net Income To Common 15 M Short Percent Of Float 0.0009
Implied Shares Outstanding 57 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 40490 Average Volume10days 40490 Total Cash 56 M
Next Fiscal Year End 1 B Revenue Per Share 2.84 Held Percent Insiders 0.0731
Ebitda Margins 18.39 % Trailing PE 21.52 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 5.81 Target Low Price 11.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 5.56 Open 5.78
Free Cashflow -7769625 Dividend Yield 0.00 % Return On Assets 0.0316
Time Zone Short Name EST Trailing Eps 0.2700 Day Low 5.67
Address1 2 Holzman Street Shares Outstanding 57 M Price Hint 2
Target High Price 20.00 Website https://www.kamada.com 52 Week Change 0.2283
Average Volume 34850 Earnings Quarterly Growth 144.30 % Forward Eps 0.3100
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 214.50 %
Is_sp_500 False Regular Market Day High 5.81 Profit Margins 9.75 %
Debt To Equity 3.41 Fifty Two Week High 6.53 Day High 5.81
Shares Short 26936 Regular Market Open 5.78 Industry Key drug-manufacturers-specialty-generic
Earnings Growth 100.00 % Enterprise To Revenue 1.79 Revenue Growth 13.40 %
Shares Percent Shares Out 0.0005 Operating Cashflow 20 M Currency USD
Time Zone Full Name America/New_York Market Cap 334 M Is_nasdaq_100 False
Zip 7670402 Quote Type EQUITY Industry Drug Manufacturers - Specialty & Generic
Long Name Kamada Ltd. Regular Market Day Low 5.67 Held Percent Institutions 0.5010
Current Price 5.81 Address2 Science Park PO Box 4081 Enterprise To Ebitda 9.71
Financial Currency USD Current Ratio 4.07 Gross Margins 42.00 %
Industry Disp Drug Manufacturers - Specialty & Generic Number Of Analyst Opinions 3 Country Israel
Float Shares 10 M Two Hundred Day Average 5.54 Enterprise Value 276 M
Price To Sales Trailing12 Months 2.16 Forward PE 16.14 Regular Market Volume 31519
Last Dividend Date 1 B Ebitda 28 M Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Kamada Ltd.

manufactures and sells plasma-derived protein therapeutics.

Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.

The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B.

In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers.

The company was incorporated in 1990 and is headquartered in Rehovot, Israel.